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The past decade has witnessed an explosion of knowledge regarding how mitochondrial
dysfunction may translate into ageing and disease phenotypes, as well as how it is modulated by
genetic and lifestyle factors. In addition to energy production, mitochondria play an important role in
regulating apoptosis, buffering calcium release, retrograde signaling to the nuclear genome, producing
reactive oxygen species (ROS), participating in steroid synthesis, signaling to the immune system,
as well as controlling the cell cycle and cell growth. Impairment of the mitochondria may be caused
by mutations or deletions in nuclear or mitochondrial DNA (mtDNA). Hallmarks of mitochondrial
dysfunction include decreased ATP production, decreased mitochondrial membrane potential, swollen
mitochondria, damaged cristae, increased oxidative stress, and decreased mitochondrial DNA
copy number.
Dysfunctional mitochondria have been implicated in ageing and in several diseases, many
of which are age-related, including mitochondrial diseases, cancers, metabolic diseases and
diabetes, inflammatory conditions, neuropathy, and neurodegenerative diseases such as Alzheimer’s,
Parkinson’s, and Huntington’s disease. Additionally, a possible link between mitochondrial
metabolism and the ubiquitin-proteasome and autophagy-lysosome systems is emerging as a novel
factor contributing to the progression of several human diseases. The purpose of the Special Issue
“Mitochondrial Dysfunction in Ageing and Diseases” published in the International Journal of Molecular
Sciences [1] was to capture reviews, perspectives, and original research articles to address the progress
and current standing in the vast field of mitochondrial biology. A total of 21 papers consisting of
17 reviews and 4 articles have been published as part of the Special Issue as detailed in Table 1. Topics
included range from mitochondrial function, cell signaling, and protein homeostasis to disorders and
diseases where mitochondrial dysfunction are implicated, such as metabolic diseases, ageing, several
age-related diseases, as well as cancer. Various therapies to counteract mitochondrial dysfunction are
also discussed.
Table 1. Summary of papers in the Special Issue, arranged by topic as pertaining to
mitochondrial dysfunction.
Authors Title Topics/Keywords Type
Ahmed et al. [2]
Genes and Pathways Involved in Adult
Onset Disorders Featuring Muscle
Mitochondrial DNA Instability
mtDNA Maintenance;
Mitochondrial Disorders Review
Arnould et al. [3] Mitochondria Retrograde Signaling and theUPRmt: Where Are We in Mammals?
Unfolded Protein
Response; Cell Signaling Review
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Table 1. Cont.
Authors Title Topics/Keywords Type
Ding et al. [4] Borrowing Nuclear DNA Helicases toProtect Mitochondrial DNA
DNA Replication and
Repair; Diseases Review
Ross et al. [5]
Mitochondrial and Ubiquitin Proteasome
System Dysfunction in Ageing and Disease:
Two Sides of the Same Coin?
Ageing and Age-Related
Diseases; Ubiquitin;
Proteasome
Review
Crescenzo et al. [6] Skeletal Muscle Mitochondrial EnergeticEfficiency and Aging Ageing; Skeletal Muscle Review
Tricarico et al. [7]
Mevalonate Pathway Blockade,
Mitochondrial Dysfunction and Autophagy:
A Possible Link
Cholesterol Synthesis;
Autophagy; Inflammation Review
Zhang et al. [8] Autophagy as a Regulatory Component ofErythropoiesis
Autophagy; Erythroid
Differentiation Review
Mikhed et al. [9]
Mitochondrial Oxidative Stress,
Mitochondrial DNA Damage and Their
Role in Age-Related Vascular Dysfunction
Ageing; Cardiovascular
Diseases; Oxidative Stress Review
Vaitkus et al. [10] Thyroid Hormone Mediated Modulation ofEnergy Expenditure
Thyroid Hormone;
Energy Expenditure Review
Forini et al. [11]
Low T3 State Is Correlated with Cardiac
Mitochondrial Impairments after Ischemia
Reperfusion Injury: Evidence from a
Proteomic Approach
Thyroid Hormone;
Cardiac Ischemia and
Reperfusion; Proteomics
Article
Forini et al. [12]
Mitochondria as Key Targets of
Cardioprotection in Cardiac Ischemic
Disease: Role of Thyroid
Hormone Triiodothyronine
Cardiac Ischemia;
Thyroid Hormone;
Cardioprotection
Review
Cimolai et al. [13] Mitochondrial Mechanisms in SepticCardiomyopathy
Septic Cardiomyopathy;
Mitophagy Review
Baburamani et al. [14]
Mitochondrial Optic Atrophy (OPA) 1
Processing Is Altered in Response to
Neonatal Hypoxic-Ischemic Brain Injury
Hypoxia-Ischemia;
Brain Injury Article
Luo et al. [15] Mitochondria: A Therapeutic Target forParkinson’s Disease?
Parkinson’s Disease;
Mitochondrial Dynamics Review
Kim et al. [16]
The Role of Mitochondrial DNA in
Mediating Alveolar Epithelial Cell
Apoptosis and Pulmonary Fibrosis
Pulmonary Fibrosis;
Sirtuins Review
Pagano et al. [17]
Current Experience in Testing
Mitochondrial Nutrients in Disorders
Featuring Oxidative Stress and
Mitochondrial Dysfunction: Rational
Design of Chemoprevention Trials
Mitochondrial Co-Factors
as Therapeutics Review
Modica-Napolitano
et al. [18]
Treatment Strategies that Enhance the
Efficacy and Selectivity of
Mitochondria-Targeted Anticancer Agents
Cancer; Combination
Therapy Review
Zhang et al. [19] Targeting Mitochondrial Function to TreatQuiescent Tumor Cells in Solid Tumors Cancer; Cancer Therapies Review
Kohno et al. [20]
Mitochondrial Transcription Factor A and
Mitochondrial Genome as Molecular
Targets for Cisplatin-Based Cancer
Chemotherapy
mtTFAM; Cancer
Chemotherapy Review
Int. J. Mol. Sci. 2016, 17, 711 3 of 5
Table 1. Cont.
Authors Title Topics/Keywords Type
Wang et al. [21]
Mitochondria-Derived Reactive Oxygen
Species Play an Important Role in
Doxorubicin-Induced Platelet Apoptosis
Chemotherapy Agent
(Doxorubicin);
Oxidative Stress
Article
Wang et al. [22]
Abnormal Mitochondrial Function and
Impaired Granulosa Cell Differentiation in
Androgen Receptor Knockout Mice
Androgen Receptor;
Reproduction Article
The Special Issue opens with three reviews describing aspects of the mitochondrial machinery
in the context of maintaining homeostasis and disease [2–4]. Ding and Liu [4] together with
Ahmed et al. [2] summarize the maintenance and replication of the mitochondrial genome, and discuss
how DNA helicases and mtDNA instability affect integrity of the mtDNA, thus contributing
to mitochondrial diseases and disorders. Mitochondrial retrograde signaling, specifically the
mitochondrial unfolded protein response, involved in proteostasis is reviewed by Arnould et al. [3].
The next five papers review the interconnectedness of mitochondrial dysfunction and protein
homeostasis in health, ageing, and diseases [5–9]. Ross et al. [5] discuss the interplay of mitochondrial
dysfunction and impairment of the ubiquitin proteasome system in ageing and disease, and provide a
hypothetical model to address the heterogeneity often described during ageing. The heterogeneity
of skeletal muscle performance in ageing is examined by Crescenzo et al. [6], taking into account the
diverse mitochondrial populations present in skeletal muscle. Tricarico et al. [7] focus on a possible
link between mitochondrial dysfunction, defective protein prenylation, and the mevalonate pathway,
crucial for cholesterol synthesis, with disease. Zhang et al. [8] describe under physiological and
pathological conditions the modulators of autophagy that regulate erythropoiesis, a process during
which mitochondria and other intracellular organelles are removed. The intersection of mtDNA
damage and oxidative stress on age-related vascular dysfunction is presented by Mikhed et al. [9],
with particular focus on nicotinamide adenosine dinucleotide phosphate (NADPH) oxidases.
We received several reviews and research articles implicating mitochondria in cardiovascular
diseases and ischemia as well as cerebral hypoxia-ischemia [11–14]. Interestingly, a few of these
contributions highlight the role of thyroid hormone [10–12]. Vaikus et al. [10] review the diverse
effects that thyroid hormone has on mitochondria and energy expenditure, including mitochondrial
biogenesis and clinical correlates. Forini et al. [12] discuss possible thyroid hormone triiodothyronine
(T3) supplementation to improve mitochondrial function in the context of ischemic heart disease.
The same research group also present findings [11] indicating that low T3 levels are correlated with
mitochondrial impairments following cardiac ischemia reperfusion injury. Mitochondrial dysfunction
is also associated with septic cardiomyopathy, a complication of sepsis, which is a serious condition
where the pathogenesis and underlying mechanisms remain unclear, as described by Cimolai et al. [13].
Findings discussed by Babiramani et al. [14] suggest that neonatal cerebral hypoxic-ischemia may alter
mitochondrial dynamics, affecting optic atrophy 1 (OPA1). Impaired mitochondrial dynamics have
also been described in neurodegenerative diseases, such as Parkinson’s disease (PD). Luo et al. [15]
review recent literature that support the role of compromised mitochondrial dynamics, mitophagy,
and mitochondrial import in PD, and also offer a list of potential therapeutics that target mitochondria.
The review by Kim et al. [16] discusses the link between mitochondrial dysfunction and alveolar
epithelial cell apoptosis in contributing to age-related lung diseases, as well as how sirtuin family
members may constitute therapeutic candidates. Mitochondrial co-factors, such as α-lipoic acid,
carnitine, and Coenzyme Q10 have been used to treat mitochondria-associated disorders and diseases,
and the results of several clinical trials using these co-factors with and without antioxidants/herbal
compounds are systematically presented by Pagano et al. [17].
A few contributions regarding the involvement of mitochondria in cancer and possible therapies
were also received [18–21]. Ever since the “Warburg effect” was described nearly a century
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ago, mitochondria have been increasingly implicated in cancer biology. Extensive research has
revealed notable differences between cancerous and healthy cells, such as altered mitochondrial
size, shape, metabolic profiles, membrane potential, as well as elevated levels of mtDNA mutations,
mitochondrial transcription factor A (TFAM), and oxidative stress [18,20]. Using these findings
to exploit mitochondria, several promising anti-cancer treatments have been developed, but have
unfortunately proven to have limitations [18–21]. Thus, researchers have recently explored alternative
strategies as summarized in Modica-Napolitano and Weissig [18] as well as targeting specific
microenvironments within tumors as discussed by Zhang et al. [19]. Moreover, the mechanisms
by which cancer cells develop drug-resistance are currently being investigated, as reviewed by
Kohno et al. [20], and possible means to mitigate the side effects of anti-cancer therapies are also
being studied by Wang et al. [21]. Collectively, these contributions focus on mitochondrial mechanisms
as an avenue to reveal possible novel interventions in order to combat cancer.
Lastly, but certainly not of least importance, recent studies of the role of mitochondrial function
in fertility and oocyte quality have been extensive. Research by Wang et al. [22] demonstrates that
androgen receptor knockout mice have poor oocyte maturating rates, impaired ATP production in
granulosa cell mitochondria, and impaired mitochondria biogenesis. Additional research is needed to
better understand how mitochondrial function may affect fertility and fecundity in order to develop
therapeutic approaches.
Overall, the 21 contributions published in the Special Issue illustrate how essential mitochondria
are to overall health and success of an organism. The involvement of mitochondria in several biological
disciplines, diseases, and disorders, ranging from cancer biology, metabolism, and proteostasis to
neurodegenerative and cardiovascular diseases is a testament to their importance and fundamental
contributions. We would like to thank all of the authors who contributed their work to the Special
Issue. The main objective was to provide ample breadth and depth to depict the interconnectedness
of mitochondrial function in ageing and mitochondrial-associated diseases. While the underlying
mechanisms linking impaired mitochondria with the ageing process and disease states remain
incompletely elucidated, the overall field of mitochondrial biology has made leaps and bounds
in only the past two decades. Based on these breakthroughs, new “mito-research” platforms have
emerged; for example, mitochondrial function in fertility or in stem cell niches. We remain hopeful
that harnessing the power of the mitochondrial network will help us stay healthy.
Acknowledgments: The Foundation for Geriatric Diseases at Karolinska Institutet (G.C.), Karolinska Institutet
Research Foundations (G.C.), Loo och Hans Ostermans Foundation for Medical Research (G.C.), the Swedish
Society for Medical Research (G.C., J.M.R.), Swedish Brain Power (G.C., J.M.R.), the Swedish Research
Council (537-2014-6856; J.M.R.), the Swedish Brain Foundation (J.M.R.), Swedish Lundbeck Foundation (J.M.R.),
and Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (J.M.R.).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Special issue “mitochondrial dysfunction in ageing and diseases”. Int. J. Mol. Sci. Available online:
http://www.mdpi.com/journal/ijms/special_issues/mitochondrial-dysfunction (accessed on 9 May 2016).
2. Ahmed, N.; Ronchi, D.; Comi, G.P. Genes and pathways involved in adult onset disorders featuring muscle
mitochondrial DNA instability. Int. J. Mol. Sci. 2015, 16, 18054–18076. [CrossRef] [PubMed]
3. Arnould, T.; Michel, S.; Renard, P. Mitochondria retrograde signaling and the UPRmt: Where are we in
mammals? Int. J. Mol. Sci. 2015, 16, 18224–18251. [CrossRef] [PubMed]
4. Ding, L.; Liu, Y. Borrowing nuclear DNA helicases to protect mitochondrial DNA. Int. J. Mol. Sci. 2015,
16, 10870–10887. [CrossRef] [PubMed]
5. Ross, J.M.; Olson, L.; Coppotelli, G. Mitochondrial and ubiquitin proteasome system dysfunction in ageing
and disease: Two sides of the same coin? Int. J. Mol. Sci. 2015, 16, 19458–19476. [CrossRef] [PubMed]
6. Crescenzo, R.; Bianco, F.; Mazzoli, A.; Giacco, A.; Liverini, G.; Iossa, S. Skeletal muscle mitochondrial
energetic efficiency and aging. Int. J. Mol. Sci. 2015, 16, 10674–10685. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 711 5 of 5
7. Tricarico, P.M.; Crovella, S.; Celsi, F. Mevalonate pathway blockade, mitochondrial dysfunction and
autophagy: A possible link. Int. J. Mol. Sci. 2015, 16, 16067–16084. [CrossRef] [PubMed]
8. Zhang, J.; Wu, K.; Xiao, X.; Liao, J.; Hu, Q.; Chen, H.; Liu, J.; An, X. Autophagy as a regulatory component of
erythropoiesis. Int. J. Mol. Sci. 2015, 16, 4083–4094. [CrossRef] [PubMed]
9. Mikhed, Y.; Daiber, A.; Steven, S. Mitochondrial oxidative stress, mitochondrial DNA damage and their role
in age-related vascular dysfunction. Int. J. Mol. Sci. 2015, 16, 15918–15953. [CrossRef] [PubMed]
10. Vaitkus, J.A.; Farrar, J.S.; Celi, F.S. Thyroid hormone mediated modulation of energy expenditure.
Int. J. Mol. Sci. 2015, 16, 16158–16175. [CrossRef] [PubMed]
11. Forini, F.; Ucciferri, N.; Kusmic, C.; Nicolini, G.; Cecchettini, A.; Rocchiccioli, S.; Citti, L.; Iervasi, G. Low T3
state is correlated with cardiac mitochondrial impairments after ischemia reperfusion injury: Evidence from
a proteomic approach. Int. J. Mol. Sci. 2015, 16, 26687–26705. [CrossRef] [PubMed]
12. Forini, F.; Nicolini, G.; Iervasi, G. Mitochondria as key targets of cardioprotection in cardiac ischemic disease:
Role of thyroid hormone triiodothyronine. Int. J. Mol. Sci. 2015, 16, 6312–6336. [CrossRef] [PubMed]
13. Cimolai, M.C.; Alvarez, S.; Bode, C.; Bugger, H. Mitochondrial mechanisms in septic cardiomyopathy.
Int. J. Mol. Sci. 2015, 16, 17763–17778. [CrossRef] [PubMed]
14. Baburamani, A.A.; Hurling, C.; Stolp, H.; Sobotka, K.; Gressens, P.; Hagberg, H.; Thornton, C. Mitochondrial
optic atrophy (OPA) 1 processing is altered in response to neonatal hypoxic-ischemic brain injury.
Int. J. Mol. Sci. 2015, 16, 22509–22526. [CrossRef] [PubMed]
15. Luo, Y.; Hoffer, A.; Hoffer, B.; Qi, X. Mitochondria: A therapeutic target for Parkinson’s disease?
Int. J. Mol. Sci. 2015, 16, 20704–20730. [CrossRef] [PubMed]
16. Kim, S.-J.; Cheresh, P.; Jablonski, R.P.; Williams, D.B.; Kamp, D.W. The role of mitochondrial DNA in
mediating alveolar epithelial cell apoptosis and pulmonary fibrosis. Int. J. Mol. Sci. 2015, 16, 21486–21519.
[CrossRef] [PubMed]
17. Pagano, G.; Aiello Talamanca, A.; Castello, G.; Cordero, M.D.; d’Ischia, M.; Gadaleta, M.N.; Pallardó, F.V.;
Petrovic´, S.; Tiano, L.; Zatterale, A. Current experience in testing mitochondrial nutrients in disorders
featuring oxidative stress and mitochondrial dysfunction: Rational design of chemoprevention trials.
Int. J. Mol. Sci. 2014, 15, 20169–20208. [CrossRef] [PubMed]
18. Modica-Napolitano, J.S.; Weissig, V. Treatment strategies that enhance the efficacy and selectivity of
mitochondria-targeted anticancer agents. Int. J. Mol. Sci. 2015, 16, 17394–17421. [CrossRef] [PubMed]
19. Zhang, X.; de Milito, A.; Olofsson, M.H.; Gullbo, J.; D’Arcy, P.; Linder, S. Targeting mitochondrial function to
treat quiescent tumor cells in solid tumors. Int. J. Mol. Sci. 2015, 16, 27313–27326. [CrossRef] [PubMed]
20. Kohno, K.; Wang, K.-Y.; Takahashi, M.; Kurita, T.; Yoshida, Y.; Hirakawa, M.; Harada, Y.; Kuma, A.; Izumi, H.;
Matsumoto, S. Mitochondrial transcription factor A and mitochondrial genome as molecular targets for
cisplatin-based cancer chemotherapy. Int. J. Mol. Sci. 2015, 16, 19836–19850. [CrossRef] [PubMed]
21. Wang, Z.; Wang, J.; Xie, R.; Liu, R.; Lu, Y. Mitochondria-derived reactive oxygen species play an important
role in Doxorubicin-induced platelet apoptosis. Int. J. Mol. Sci. 2015, 16, 11087–11100. [CrossRef] [PubMed]
22. Wang, R.-S.; Chang, H.-Y.; Kao, S.-H.; Kao, C.-H.; Wu, Y.-C.; Yeh, S.; Tzeng, C.-R.; Chang, C. Abnormal
mitochondrial function and impaired granulosa cell differentiation in androgen receptor knockout mice.
Int. J. Mol. Sci. 2015, 16, 9831–9849. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
